LeMaitre Vascular demonstrates accelerating double-digit revenue growth (13.5% YoY TTM) with gross margin expansion to 72.1% in Q2 2026, driven by niche pricing power and Artegraft international expansion. Operating leverage is evident as operating margin impr...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | $0.74-8.3% vs $0.81 | $70M-1.5% vs $71M |
Q2 2026 May 5, 2026 | $0.68+3.0% vs $0.66 | $67M-0.2% vs $67M |
Q1 2026 Feb 25, 2026 | $0.68+1.5% vs $0.67 | $64M+2.6% vs $63M |
Q4 2025 Nov 6, 2025 | $0.62+9.9% vs $0.56 | $61M-1.8% vs $62M |
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and LeMaitre Vascular (LMAT). But which of these two stocks is more attractive to value investors?
BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences.
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and LeMaitre Vascular (LMAT). But which of these two stocks presents investors with the better value opportunity right now?
Benchmark LMAT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for LeMaitre Vascular, Inc. (LMAT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $80.58 | $1.84B | 31.98 | 13.53% | 23.13% | 15.8% | 0.98% | |
| $59.96 | $3.05B | -249.81 | 14.88% | 1.85% | 2.14% | — | |
| $16.25 | $1.88B | -13.32 | 8.28% | -21.25% | -44% | — | |
| $15.51 | $641.07M | -17.63 | 9.46% | -11.48% | -21.01% | — | |
| $45.80 | $1.37B | 30.33 | 5.16% | 4.12% | 5.51% | — | |
| $87.07 | $5.19B | 40.88 | 11.66% | 9.22% | 9.07% | — |
LeMaitre Vascular, Inc. (LMAT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
LeMaitre Vascular, Inc. (LMAT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
Jun 5, 2026·SEC
May 5, 2026·SEC
Get notified when LMAT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LeMaitre Vascular, Inc. (LMAT) stock FAQ — growth, dividends, profitability & financials explained
LeMaitre Vascular, Inc. (LMAT) reported $262.4M in revenue for fiscal year 2025. This represents a 902% increase from $26.2M in 2004.
LeMaitre Vascular, Inc. (LMAT) grew revenue by 13.5% over the past year. This is steady growth.
Yes, LeMaitre Vascular, Inc. (LMAT) is profitable, generating $65.7M in net income for fiscal year 2025 (23.1% net margin).
Yes, LeMaitre Vascular, Inc. (LMAT) pays a dividend with a yield of 0.98%. This makes it attractive for income-focused investors.
LeMaitre Vascular, Inc. (LMAT) has a return on equity (ROE) of 15.8%. This is reasonable for most industries.
LeMaitre Vascular, Inc. (LMAT) generated $73.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
